Effect of Yiguan Decoction on the efficacy of M1 bone marrow-derived macrophages in treatment of liver cirrhosis rats and its mechanism

Mengyao ZONG; Xun JIAN; Danyang WANG; Yannan XU; Xinrui ZHENG; Feifei XING; Gaofeng CHEN; Jiamei CHEN; Ping LIU; Yongping MU

doi:10.12449/JCH240817

Volume 40 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(8): 1612-1619

PDF( 4914 KB)

Effect of Yiguan Decoction on the efficacy of M1 bone marrow-derived macrophages in treatment of liver cirrhosis rats and its mechanism

DOI: 10.12449/JCH240817

Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Institute of Liver Diseases，Shuguang Hospital，Shanghai University of Traditional Chinese Medicine，Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China

Research funding:

General Project of National Natural Science Foundation of China (81874390);

Shanghai Natural Science Foundation (21ZR1464100);

Special Project for Biomedical Science and Technology Support of the “Science and Technology Innovation Action Plan” of Shanghai Science and Technology Commission in 2022 (22S11901700);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

More Information

Corresponding author: MU Yongping， ypmu8888@126.com （ORCID： 0000-0002-6808-8243）
Received Date: 2023-11-24
Accepted Date: 2024-01-29
Published Date: 2024-08-25

Abstract

Abstract

Objective To investigate the effect and mechanism of Yiguan Decoction （YGJD） on the efficacy of M1 bone marrow-derived macrophages （M1-BMDMs） in the treatment of rats with liver cirrhosis induced by 2-AAF/CCl₄. Methods BMDMs were isolated and induced into M1-BMDMs by lipopolysaccharide. A total of 50 male Wistar rats were randomly divided into normal group with 5 rats and model group with 45 rats. The rats for modeling were given subcutaneous injection of 50% CCl₄ twice a week. Since week 7， the rats for modeling were randomly divided into model group （M group）， YGJD group， M1-BMDM group， M1-BMDM+YGJD group， and sorafenib （SORA） group， and they were given subcutaneous injection of 30% CCl₄ to maintain the progression of liver cirrhosis and intragastric administration of 2-AAF. CCR2 inhibitors were added to the drinking water， and each group was given the corresponding intervention. Related samples were collected at week 9. The rats were observed in terms of serum liver function parameters， liver pathology， hydroxyproline （Hyp） content in liver tissue， hepatic stellate cell activation， hepatic fibrosis and inflammation factors， and the expression levels of molecules associated with the Wnt signaling pathway. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results Compared with the M group， the M1-BMDM+YGJD group had significant reductions in the serum levels of alanine aminotransferase， aspartate aminotransferase， and total bilirubin （TBil）（all P<0.05） and a significant increase in the content of albumin （Alb）（P<0.05）， and compared with the M1-BMDM group， the M1-BMDM+YGJD group had a significant reduction in the serum level of TBil （P<0.05） and a significant increase in the serum level of Alb （P<0.05）. Compared with the M1-BMDM group， the M1-BMDM+YGJD group had significant reductions in the expression levels of CD68 and TNF-α （P<0.05）. Compared with the M1-BMDM group， the M1-BMDM+YGJD group had significant reductions in Hyp content and Sirius red positive area （P<0.05）. As for the non-canonical Wnt signaling pathway molecules， compared with the M1-BMDM group， the M1-BMDM+YGJD group had significantly lower mRNA and protein expression levels of Wnt5a （P<0.05） and mRNA expression level of Fzd2 （P<0.05）， as well as significant reductions in the mRNA expression levels of Wnt4， Wnt5b， and Fzd3 （P<0.05）， while there were no significant changes in the mRNA expression levels of the canonical Wnt signaling pathway molecules β-catenin， LRP5， LRP6， Fzd5， and TCF. Conclusion YGJD can enhance the therapeutic effect of M1-BMDMs on rats with liver cirrhosis induced by 2-AAF/CCl₄， possibly by inhibiting the non-canonical Wnt5a/Fzd2 signaling pathway， which provides new ideas for the synergistic effect of traditional Chinese medicine on M1-BMDMs in the treatment of liver cirrhosis.
- Liver Cirrhosis,
- Macrophages,
- Yi Guan Jian,
- Wnt Signaling Pathway,
- Rats， Wistar

FullText(HTML)

References(27)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j. issn.1001-5256.2019.11.006.
[2]	FREEMAN RB Jr, STEFFICK DE, GUIDINGER MK, et al. Liver and intestine transplantation in the United States, 1997-2006[J]. Am J Transplant, 2008, 8( 4 Pt 2): 958- 976. DOI: 10.1111/j.1600-6143.2008.02174.x.
[3]	ZHANG YT, LI YW, ZHANG LL, et al. Mesenchymal stem cells: Potential application for the treatment of hepatic cirrhosis[J]. Stem Cell Res Ther, 2018, 9( 1): 59. DOI: 10.1186/s13287-018-0814-4.
[4]	SICA A, INVERNIZZI P, MANTOVANI A. Macrophage plasticity and polarization in liver homeostasis and pathology[J]. Hepatology, 2014, 59( 5): 2034- 2042. DOI: 10.1002/hep.26754.
[5]	LIU ZR, WAN XY, WANG ZL, et al. Electroactive biomaterials and systems for cell fate determination and tissue regeneration: Design and applications[J]. Adv Mater, 2021, 33( 32): e2007429. DOI: 10.1002/adma.202007429.
[6]	HEISSIG B, DHAHRI D, EIAMBOONSERT S, et al. Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression[J]. Cell Mol Life Sci, 2015, 72( 24): 4759- 4770. DOI: 10.1007/s00018-015-2035-7.
[7]	LANZONI G, OIKAWA T, WANG Y, et al. Concise review: clinical programs of stem cell therapies for liver and pancreas[J]. Stem Cells, 2013, 31( 10): 2047- 2060. DOI: 10.1002/stem.1457.
[8]	TACKE F. Targeting hepatic macrophages to treat liver diseases[J]. J Hepatol, 2017, 66( 6): 1300- 1312. DOI: 10.1016/j.jhep.2017.02.026.
[9]	JIAN X, WANG DY, XU YN, et al. Effect of polarized bone marrow-derived macrophage transplantation on the progression of CCl₄-induced liver fibrosis in rats[J]. J Clin Hepatol, 2021, 37( 12): 2830- 2837. DOI: 10.3969/j.issn.1001-5256.2021.12.020. 简迅, 王丹阳, 许燕楠, 等. 极化骨髓巨噬细胞移植对CCl₄诱导的肝纤维化大鼠模型的影响[J]. 临床肝胆病杂志, 2021, 37( 12): 2830- 2837. DOI: 10.3969/j.issn.1001-5256.2021.12.020.
[10]	XU Y, XU W, LIU W, et al. Yiguanjian decoction inhibits macrophage M1 polarization and attenuates hepatic fibrosis induced by CCl₄/2-AAF[J]. Pharm Biol, 2021, 59( 1): 1150- 1160. DOI: 10.1080/13880209.2021.1961820.
[11]	DAVIS BK. Derivation of macrophages from mouse bone marrow[J]. Methods Mol Biol, 2019, 1960: 41- 55. DOI: 10.1007/978-1-4939-9167-9_3.
[12]	WATANABE Y, TSUCHIYA A, SEINO S, et al. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice[J]. Stem Cells Transl Med, 2019, 8( 3): 271- 284. DOI: 10.1002/sctm.18-0105.
[13]	MILY A, KALSUM S, LORETI MG, et al. Polarization of M1 and M2 human monocyte-derived cells and analysis with flow cytometry upon mycobacterium tuberculosis infection[J]. J Vis Exp, 2020. DOI: 10.3791/61807.
[14]	GAO Z, JIANG JN, HOU LJ, et al. Dysregulation of miR-144-5p/RNF187 axis contributes to the progression of colorectal cancer[J]. J Transl Int Med, 2022, 10( 1): 65- 75. DOI: 10.2478/jtim-2021-0043.
[15]	CHEN L, MU YP, ZHANG H, et al. Research progress on mechanism of Yiguanjian intervention in liver cirrhosis[J]. Chin J Exp Med Formul, 2020, 26( 24): 186- 192. DOI: 10.13422/j.cnki.syfjx.20202437. 陈龙, 慕永平, 张华, 等. 一贯煎干预肝硬化作用机制研究进展[J]. 中国实验方剂学杂志, 2020, 26( 24): 186- 192. DOI: 10.13422/j.cnki.syfjx.20202437.
[16]	XU LW, DENG XJ, ZHU LD, et al. Research progress of differentiating and treating lung cancer from the liver with Yiguanjian[J]. Chin J Exp Med Formul, 2022, 38( 1): 114- 117. DOI: 10.13463/j.cnki.cczyy.2022.01.027. 徐丽伟, 邓小静, 朱立德, 等. 一贯煎从肝论治肺癌的研究进展[J]. 长春中医药大学学报, 2022, 38( 1): 114- 117. DOI: 10.13463/j.cnki.cczyy.2022.01.027.
[17]	ESHGHJOO S, KIM DM, JAYARAMAN A, et al. Macrophage polarization in atherosclerosis[J]. Genes(Basel), 2022, 13( 5): 756. DOI: 10.3390/genes13050756.
[18]	MA PF, GAO CC, YI J, et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice[J]. J Hepatol, 2017, 67( 4): 770- 779. DOI: 10.1016/j.jhep.2017.05.022.
[19]	TSUCHIDA T, FRIEDMAN SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14( 7): 397- 411. DOI: 10.1038/nrgastro.2017.38.
[20]	SCHWABE RF, TABAS I, PAJVANI UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis[J]. Gastroenterology, 2020, 158( 7): 1913- 1928. DOI: 10.1053/j.gastro.2019.11.311.
[21]	LIASKOU E, ZIMMERMANN HW, LI KK, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics[J]. Hepatology, 2013, 57( 1): 385- 398. DOI: 10.1002/hep.26016.
[22]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
[23]	BAARSMA HA, KÖNIGSHOFF M.‘WNT-er is coming’: WNT signalling in chronic lung diseases[J]. Thorax, 2017, 72( 8): 746- 759. DOI: 10.1136/thoraxjnl-2016-209753.
[24]	ZENG G, AWAN F, OTRUBA W, et al. Wnt’er in liver: Expression of Wnt and frizzled genes in mouse[J]. Hepatology, 2007, 45( 1): 195- 204. DOI: 10.1002/hep.21473.
[25]	SAHA S, ARANDA E, HAYAKAWA Y, et al. Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury[J]. Nat Commun, 2016, 7: 13096. DOI: 10.1038/ncomms13096.
[26]	LIU WT, JING YY, GAO L, et al. Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment[J]. Cell Death Differ, 2020, 27( 1): 85- 101. DOI: 10.1038/s41418-019-0340-7.
[27]	ZHANG Y, ZHU Y. Efficacy studies of Yiguanjian treatment in mice fibrosis induced by dimethylnitrosamine[J]. J Dalian Med Univ, 2014, 36( 6): 527- 535, 596. DOI: 10.11724/jdmu.2014.06.04. 张媛, 朱英. 一贯煎治疗二甲基亚硝胺致小鼠肝纤维化的机制研究[J]. 大连医科大学学报, 2014, 36( 6): 527- 535, 596. DOI: 10.11724/jdmu.2014.06.04.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4)

Get Citation

PDF

XML

Article Metrics

Article views (136) PDF downloads(16)

Effect of Yiguan Decoction on the efficacy of M1 bone marrow-derived macrophages in treatment of liver cirrhosis rats and its mechanism

DOI: 10.12449/JCH240817

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content